# Setrusumab vs Placebo for Osteogenesis Imperfecta

> **NCT05125809** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Ultragenyx Pharmaceutical Inc** · enrollment: 183 (actual)

## Conditions studied

- Osteogenesis Imperfecta

## Interventions

- **BIOLOGICAL:** Setrusumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05125809
- **Lead sponsor:** Ultragenyx Pharmaceutical Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-21
- **Primary completion:** 2025-10-20
- **Final completion:** 2027-04
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05125809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05125809, "Setrusumab vs Placebo for Osteogenesis Imperfecta". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05125809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*